

Summit Corporation plc
 ('Summit' or 'the Company')

AWARD OF SHARE OPTIONS

Oxford, UK, 1 February 2013 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and *C. difficile* infections, announces that on 31 January 2013 it granted Share Options under its existing Company Share Option Scheme Rules ('the Scheme') to Executive Officers of the Company as follows:

Executive Officer	Position	Number of Options Granted	Exercise Price
Glyn Edwards	Chief Executive Officer	1,459,459	1.0 pence
Raymond Spencer	Chief Financial Officer	354,730	1.0 pence

The Share Options are being granted as a consequence of the Board of Directors agreeing to implement the recommendation from the Remuneration Committee that bonus awards be made to the Executive Officers in recognition of the achievement of individual and company performance targets during the year ended 31 January 2013. The Executive Officers agreed to receive this award in the form of the Share Options as described above. The Board believes that the awards are aligned with shareholder interests to promote growth in the value of the Company and to help incentivise and retain senior executive officers in the Company.

The options may be exercised between 31 July 2013 and 31 January 2023. The total number of options being granted represents 0.5% of the Company's current issued share capital.

- END -

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 951

Nomura Code Securities

(Nominated Adviser and Joint broker)

Chris Collins / Jonathan Senior / Giles Balleny

Tel: +44 (0)20 7776 1200

Hybridan LLP

(Joint broker)

Claire Louise Noyce / Deepak Reddy

Tel: +44 (0)207 947 4350

Peckwater PR

(Financial public relations, UK)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)

Michelle Avery

Tel: +1 781-235-3060

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.

Forward Looking Statements

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.